Geriatrics

  • Bone turnover markers to monitor oral bisphosphonate therapy
    CME article
    Nikita Ashcherkin, MD, Archna A. Patel, MD, MPH, Alicia Algeciras-Schimnich, PhD and Krupa B. Doshi, MD, FACE
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 26-31; DOI: https://doi.org/10.3949/ccjm.90a.22002

    Rapid changes in levels of bone turnover markers can be useful in monitoring the effectiveness of therapy and improving adherence to therapy.

  • Making best use of bone turnover markers to monitor oral bisphosphonate therapy
    Sarah Keller, MD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 32-34; DOI: https://doi.org/10.3949/ccjm.90a.22092

    Clinical applications of bone turnover markers can include determining when to start or end a bisphosphonate “holiday” and measuring treatment response.

  • Geriatric update 2022: Preventing Alzheimer disease and more
    Melissa Morgan-Gouveia, MD, Kathleen Drago, MD, FACP, Patricia Harris, MD, MS and Meera Sheffrin, MD, MAS
    Cleveland Clinic Journal of Medicine November 2022, 89 (11) 617-624; DOI: https://doi.org/10.3949/ccjm.89a.21094

    Key topics include Alzheimer dementia, effects of frailty and social isolation, COVID-19 risks in patients with dementia, hospital-at-home programs, deprescribing antihypertensive drugs, bisphosphonate-related fractures, and cannabis use.

  • Managing stage 1 hypertension: Consider the risks, stop the progression
    Abel Hooker, MD, Kevin G. Buda, DO and Maarya Pasha, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 244-248; DOI: https://doi.org/10.3949/ccjm.89a.21101

    Guidelines on managing patients with stage 1 hypertension and a low 10-year risk of atherosclerotic cardiovascular disease.

  • Palliative care: An update for internists
    Rachel D. Havyer, MD, FAAHPM, Nauzley Abedini, MD, MSc, Robert L. Jayes, MD, Brenda Matti-Orozco, MD, Daniel H. Pomerantz, MD, MPH and Aziz A. Ansari, DO, SFHM, FAAHPM, FACP
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 262-268; DOI: https://doi.org/10.3949/ccjm.89a.21075

    A review of recent research to guide symptom management, advance-care planning, and communication training to maximize compassionate care.

  • Treating anemia: It’s not just the EPO
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 174-175; DOI: https://doi.org/10.3949/ccjm.89b.04022

    Long-term effects of treatment with the new oral inhibitors of prolyl hydroxylase will need to be carefully monitored, as prolyl hydroxylase is a key structural component of diverse proteins.

  • Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Tarek Souaid, MD, Jonathan Taliercio, DO, James F. Simon, MD, MBA, Ali Mehdi, MD, MEd and Georges N. Nakhoul, MD, MEd
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 212-222; DOI: https://doi.org/10.3949/ccjm.89a.21100

    A review of the pathophysiology of anemia of chronic kidney disease, major clinical trials, and novel therapies.

  • Potential systemic benefits of shocking or blocking nerves
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 119-120; DOI: https://doi.org/10.3949/ccjm.89b.03022

    What has really caught my attention is the expanding research on controlled regional neuromodulation and its impact on systemic physiology and inflammation.

  • Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
    Yeonsoo Sara Lee, BS, Christopher Wie, MD, Scott Pew, MD and Juliana M. Kling, MD, MPH
    Cleveland Clinic Journal of Medicine March 2022, 89 (3) 147-153; DOI: https://doi.org/10.3949/ccjm.89a.21032

    Hormone therapy is the mainstay of treatment, but there is a clear need for safe and effective nonhormonal options. The authors review data on the use of stellate ganglion block in perimenopausal and postmenopausal patients.

  • Hypercalcemia and vitamin A: A vitamin to keep in mind
    Saif Munther Borgan, MD, Leila Zeinab Khan, MD and Vinni Makin, MD, FACE
    Cleveland Clinic Journal of Medicine February 2022, 89 (2) 99-105; DOI: https://doi.org/10.3949/ccjm.89a.21056

    Vitamin A toxicity can affect bone resorption and hypercalcemia and should be explored in unexplained cases of parathyroid hormone-independent hypercalcemia.

Pages